Efficacy and safety of paclitaxel/ramucirumab as the second-line chemotherapy in Japanese patients with advanced gastric cancer.

被引：1
|
作者：
Kusumoto, Tetsuya
Egashira, Akinori
Sonoda, Hideto
Hashimoto, Kenkichi
Uehara, Hideo
Kusumoto, Eiji
Shinzato, Chiaki
Uchino, Keita
Sakaguchi, Yoshihisa
Ikejiri, Koji
Maehara, Yoshihiko
机构：
[1] Natl Kyushu Med Ctr, Dept Gastrointestinal Surg, Fukuoka, Fukuoka, Japan
[2] Natl Kyushu Med Ctr, Clin Res Ctr Canc Res Div, Fukuoka, Fukuoka, Japan
[3] Natl Kyusyu Med Ctr, Dept Med Oncol, Fukuoka, Fukuoka, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Fukuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15540
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15540
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Chemotherapy beyond second-line in advanced gastric cancer
    Kim, Sung Min
    Park, Se Hoon
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (29) : 8811 - 8816
  • [42] Nab-paclitaxel plus ramucirumab combination therapy as second-line with advanced gastric cancer:Retrospective study
    Kashiwada, Tomomi
    Nishioka, Atsujiro
    Komiya, Kazutoshi
    Aragane, Naoko
    Kimura, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 140 - 140
  • [43] Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
    Giandomenico Roviello
    Catalano Martina
    Costanza Winchler
    Irene De Gennaro Aquino
    Francesca Papa
    Eleonora Buttitta
    Gemma Rossi
    Lorenzo Antonuzzo
    Journal of Gastrointestinal Cancer, 2023, 54 : 802 - 808
  • [44] Evaluation of the safety of ramucirumab in Japanese patients with advanced gastric cancer
    Iwai, M.
    Ito, D.
    Asano, H.
    Adachi, S.
    Okada, K.
    Kimura, M.
    Usami, E.
    Matsuo, K.
    Yoshimura, T.
    Teramachi, H.
    PHARMAZIE, 2018, 73 (05): : 309 - 312
  • [45] A Phase I/II trial of fruquintinib in combination with paclitaxel for second-line treatment in patients with advanced gastric cancer.
    Xu, Rui-hua
    Zhang, Dongsheng
    Shen, Lin
    Li, Jin
    Huang, Jing
    Gong, Jifang
    Guo, Weijian
    Zhang, Yang
    Fan, Songhua
    Li, Ke
    Hua, Ye
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] An investigator initiated multicenter phase I/II study of paclitaxel, ramucirumab with nivolumab as the second-line treatment in patients with metastatic gastric cancer.
    Nishina, Tomohiro
    Hironaka, Shuichi
    Kadowaki, Shigenori
    Yamanaka, Takeharu
    Nakajima, Takako Eguchi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Second line chemotherapy with paclitaxel and Carboplatin in advanced gastric cancer
    Papakostas, P
    Rigatos, S
    Stathopoulos, GP
    Samelis, G
    Polyzos, A
    Fountzilas, G
    ANNALS OF ONCOLOGY, 1998, 9 : 50 - 50
  • [48] Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer.
    Takahari, Daisuke
    Wakatsuki, Takeru
    Mashima, Tetsuo
    Chin, Keisho
    Ichimura, Takashi
    Ogura, Mariko
    Matsushima, Tomohiro
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Shinozaki, Eiji
    Suenaga, Mitsukuni
    Kawata, Naomi
    Horiike, Yuki
    Seimiya, Hiroyuki
    Fujita, Naoya
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Multicenter phase I/II study of nivolumab combined with paclitaxel plus ramucirumab as the second-line treatment in patients with advanced gastric cancer
    Kadowaki, S.
    Izawa, N.
    Minashi, K.
    Nishina, T.
    Yamanaka, T.
    Muro, K.
    Sunakawa, Y.
    Hironaka, S.
    Kajiwara, T.
    Kawakami, Y.
    Nakajima, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Effects of weekly paclitaxel as a second-line anticancer chemotherapy for patients with advanced and recurrent gastric carcinoma
    Sakurai, Y
    Yoshida, I
    Masui, T
    Tonomura, S
    Shoji, M
    Nakamura, Y
    Uyama, I
    Komori, Y
    Kamoshida, S
    Tsutsumi, Y
    Ochiai, M
    Proceedings of the 6th International Gastric Cancer Congress, 2005, : 163 - 167
12345